Claude for Science: A Critical Look at What It Actually Delivers in Biotech R&D

Over the past year, I have watched research teams at biotech SMEs move from "should we try this" to "we use this daily" faster than with almost any other tool category I have introduced into a lab or R&D group. Claude and comparable large language models now sit in the daily workflow of bench scientists, regulatory writers, and R&D leads — summarising papers, drafting protocols, restructuring messy assay data, and increasingly, being asked to weigh in on scientific interpretation itself.

Some of that enthusiasm is earned. Some of it is not. The distinction matters more in life science than almost anywhere else, because the cost of an uncritical answer is not a bad email — it is a flawed experimental design, a misread dataset, or a compliance gap that surfaces during an audit.

Where the capability is genuinely strong

Literature synthesis at scale is the clearest win. Asking a model to work through forty papers on a target class, extract methodology details, and flag contradictions between studies is a task that used to consume a postdoc's week. It now takes an afternoon, with the model doing the first pass and a domain expert doing the verification. The value is real because the task is bounded: the source material exists, the claims can be checked against it, and the output is a starting point, not a final answer.

Restructuring and normalising messy data is similarly strong. Inconsistent plate layouts, half-documented Excel sheets inherited from a departed colleague, free-text fields that should have been categorical — this is exactly the kind of pattern-matching and reformatting work language models handle well, provided a human defines the target structure and checks the output against the source.

Drafting, not deciding is where the tool earns its keep across the board. First drafts of SOPs, protocol sections, or grant narrative text save real time. The operative word is draft. Nobody in a functioning organisation would submit that text unreviewed, and the same discipline needs to apply here.

Where the confidence is misplaced

Benchmark performance is not domain reliability. Claude and its peers score well on standardised science and biomedical QA benchmarks. That tells you something about general scientific knowledge. It tells you very little about whether the model's interpretation of your specific, narrow, proprietary dataset is correct. Your assay is not in the training distribution. Your edge case was not in the benchmark. The gap between "answers PhD-qualifying-exam-style questions well" and "correctly interprets your Western blot densitometry data" is larger than the marketing suggests, and it is precisely the gap most researchers do not test for before trusting an output.

Fabricated specificity is the most dangerous failure mode, because it does not look like a failure. A model that invents a plausible-sounding citation, a wrong-but-confident assay parameter, or a methodology detail that sounds correct but was never in the source material, is far more dangerous than one that says "I don't know." I have seen draft protocols with invented reference concentrations that were internally consistent, well-formatted, and wrong. The formatting quality of the output has no correlation with its accuracy — if anything, the two are inversely related, because well-formatted confident text is what slips past review fastest.

Novelty is where the tool is weakest and the temptation is strongest. The genuinely interesting scientific questions — the ones worth asking a model for help on — are, by definition, at the edge of or outside its training distribution. That is exactly where hallucination risk is highest and exactly where researchers are most tempted to treat a fluent, well-reasoned-sounding answer as validation of a hypothesis rather than as a starting point for one.

The data integrity problem nobody is documenting

This is the part that gets lost in the general enthusiasm, and it is the part that matters most for a regulated environment. ALCOA+ principles — attributable, legible, contemporaneous, original, accurate, and the extended criteria of complete, consistent, enduring, and available — were not written with generative AI output in mind, but they apply to it anyway. If an AI-drafted interpretation of exploratory data quietly becomes part of a study rationale without a documented human verification step, that is an undocumented data integrity gap. It will not be visible until an auditor asks "who reviewed this and on what basis," and "the model seemed confident" is not an answer that survives that question.

The practical fix is not complicated, but it does require discipline that most teams have not yet built: treat every AI-assisted output the same way you would treat a junior team member's first draft. Someone with the competence to catch an error reviews it, the review is documented, and the AI's role in producing the draft is recorded rather than quietly erased in the final version. That is not bureaucracy for its own sake — it is the same standard already applied to human-authored work in a functioning QMS, extended to a new type of author.

The right level of enthusiasm

None of this is an argument against using Claude or similar tools in biotech R&D. It is an argument against the specific failure mode I see most often, which is treating fluency as evidence. A model that writes a well-structured, confident paragraph about your data has told you nothing about whether that paragraph is correct. The teams getting real, sustained value from these tools are the ones who have internalised that distinction — who use the model to compress the time between "blank page" and "reviewable draft," while keeping the verification step exactly where it has always belonged: with a qualified human, documented, and repeatable.

That is a less exciting story than the one currently circulating in most conference talks. It is also the only one that holds up in an audit.

---

If your R&D or regulatory team is adopting AI tools faster than your review processes have adapted to them, that gap is worth closing before it shows up as a finding. I help life science organisations build AI governance that keeps pace with actual usage — get in touch if that gap sounds familiar.